Abstract

BackgroundFemale sterilization is the second most commonly used method of contraception in the United States. Female sterilization can now be performed through laparoscopic, abdominal, or hysteroscopic approaches. The hysteroscopic sterilization may be a safer option than sterilization through laparoscopy or laparotomy because it avoids invading the abdominal cavity and undergoing general anaesthesia. Hysteroscopic sterilization mainly includes chemical agents and mechanical devices. Common issues related to the toxicity of the chemical agents used have raised concerns regarding this kind of contraception. The difficulty of the transcervical insertion of such mechanical devices into the fallopian tubes has increased the high incidence of device displacement or dislodgment. At present, Essure® is the only commercially available hysteroscopic sterilization device being used clinically. The system is irreversible and is not effective immediately.Presentation of the hypothesisOur new hysteroscopic sterility system consists of nickel-titanium (NiTi) shape memory alloy and a waterproof membrane. The NiTi alloy is covered with two coatings to avoid toxic Ni release and to prevent stimulation of epithelial tissue growth around the oviducts. Because of the shape memory effect of the NiTi alloy, the device works like an umbrella: it stays collapsed at low temperature before placement and opens by the force of shape memory activated by the body temperature after it is inserted hysteroscopically into the interstitial tubal lumen. The rim of the open device will incise into interstitial myometrium during the process of unfolding. Once the device is fixed, it blocks the tube completely. When the patient no longer wishes for sterilization, the device can be closed by perfusing liquid with low temperature into the uterine cavity, followed by prospective hysteroscopic removal. After the device removal, the fallopian tube will revert to its physiological functions.Testing the hypothesisCurrently, experimental and clinical studies are needed to attest the safety, efficiency and reversibility of the novel sterilization device.Implications of the hypothesisIf our hypothesis is confirmed, appropriate and reversible contraceptive can be achieved with the device we have designed, which may have significant repercussions for numerous women worldwide.

Highlights

  • Female sterilization is the second most commonly used method of contraception in the United States

  • Hysteroscopic sterilization is a safer option than sterilization through laparoscopy or laparotomy because it avoids abdominal cavity invasion and the use of general anaesthesia

  • Scholars around the world devote themselves to the research of new technologies for female sterilization, including methods that involve tubal occlusion, mainly by using chemical agents combined with a sclerosing agent [5], cyanoacrylate [6], n-butyl-2-cyanoacrylate adhesive [7], and polidocanol [8]

Read more

Summary

Introduction

Female sterilization is the second most commonly used method of contraception in the United States. Testing the hypothesis: Currently, experimental and clinical studies are needed to attest the safety, efficiency and reversibility of the novel sterilization device. It is the only commercially available hysteroscopic sterilization device used in clinical practice, since the Adiana® Permanent Contraception System (Hologic, Inc., Bedford, MA, USA), approved by the FDA in 2009, was removed from the US market by the manufacturer in 2012 [19,20].

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call